In a filing, Arrowhead Pharmaceuticals Inc. revealed its Chief Commercial Officer Oliver Tracie unloaded Company’s shares for reported $0.24 million on Jul 02 ’24. In the deal valued at $25.28 per share,9,394 shares were sold. As a result of this transaction, Oliver Tracie now holds 127,107 shares worth roughly $2.3 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Vakiener Victoria sold 1,799 shares, generating $41,935 in total proceeds. Upon selling the shares at $23.31, the Director now owns 30,205 shares.
Before that, Hamilton James C sold 6,000 shares. Arrowhead Pharmaceuticals Inc. shares valued at $168,180 were divested by the Chief Discovery/Trans Medicine at a price of $28.03 per share. As a result of the transaction, Hamilton James C now holds 204,851 shares, worth roughly $3.71 million.
Goldman initiated its Arrowhead Pharmaceuticals Inc. [ARWR] rating to a Neutral in a research note published on June 05, 2024; the price target was $31. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Citigroup began covering ARWR with “Neutral” recommendation on September 19, 2023. TD Cowen started covering the stock on July 21, 2023. It rated ARWR as “an Outperform”.
Price Performance Review of ARWR
On Monday, Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] saw its stock fall -3.67% to $18.13. Over the last five days, the stock has lost -6.40%. Arrowhead Pharmaceuticals Inc. shares have fallen nearly -40.75% since the year began. Nevertheless, the stocks have fallen -29.04% over the past one year. While a 52-week high of $39.83 was reached on 01/10/24, a 52-week low of $18.15 was recorded on 10/07/24. SMA at 50 days reached $22.68, while 200 days put it at $26.83.
Levels Of Support And Resistance For ARWR Stock
The 24-hour chart illustrates a support level at 17.68, which if violated will result in even more drops to 17.23. On the upside, there is a resistance level at 18.73. A further resistance level may holdings at 19.34. The Relative Strength Index (RSI) on the 14-day chart is 28.20, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.05, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.02%. Stochastics %K at 13.80% indicates the stock is a buying.
How much short interest is there in Arrowhead Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Arrowhead Pharmaceuticals Inc. stocks on 2024-09-13, dropping by -1.4 million shares to a total of 9.05 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 10.45 million shares. There was a decline of -15.44%, which implies that there is a negative sentiment for the stock.
